Strategic Board Appointments PanTher recently expanded its leadership and governance with the addition of Tim Clackson to the Board of Directors and appointed John Edwards as Executive Chair. This signals a maturing company poised for strategic partnerships, fundraising, and potential collaboration opportunities with life sciences investors and strategic acquirers.

Clinical Stage Focus As a clinical-stage oncology company with a lead candidate PTM-101 already evaluated in a Phase 1 trial for localized non-metastatic pancreatic cancer, PanTher represents an opportunity to engage with researchers, contract research organizations, and biopharma for potential co-development, out-licensing, or pivotal trial collaborations.

Localized Delivery Advantage Sagittari platform enables continuous, high-dose therapy at the tumor site with reduced systemic toxicity, offering a compelling value proposition for hospitals, academic centers, and biotech partners seeking to enhance local tumor control for solid tumors.

Geographic and Funding Footprint Expansion to Texas and CPRIT grant support, along with ongoing fundraising, indicate a readiness to scale operations in the U.S. market and pursue grant-supported initiatives. This creates opportunities for regional vendors, CROs, and grant consultants to engage PanTher in support roles.

Market Positioning With a small team and a focus on solid tumors, PanTher could be an attractive partner for specialized CROs, contract manufacturers, and service providers that cater to early-stage biotech firms, enabling collaborations on manufacturing, regulatory support, and clinical development services.